Skip to main content
Clinical Trials/JPRN-UMIN000006453
JPRN-UMIN000006453
Recruiting
Phase 2

Assessment of the Efficacy of Preoperative Exemestane Therapy for Endocrine-sensitive Postmenopausal Breast Cancer (SBCCSG-23) - Assessment of the Efficacy of Preoperative Exemestane Therapy for Endocrine-sensitive Postmenopausal Breast Cancer (SBCCSG-23)

PO Saitama Breast Cancer Clinical Study Group (SBCCSG)0 sites60 target enrollmentOctober 3, 2011
ConditionsBreast cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breast cancer
Sponsor
PO Saitama Breast Cancer Clinical Study Group (SBCCSG)
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 3, 2011
End Date
September 1, 2018
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
PO Saitama Breast Cancer Clinical Study Group (SBCCSG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Exclusion criteria (1\)Patients already receiving breast cancer treatment either with chemotherapy or endocrine therapy; (2\)Patients who have a history of breast cancer. However, a patient can be considered eligible if the patient has metachronous bilateral breast cancer and it has been 10 years or more since the patient underwent surgery for contralateral breast cancer; (3\)Patients who have active multiple primary cancer; (4\)Patients who should receive surgery, chemotherapy or molecular targeted therapy instead of endocrine therapy as first line treatment; (5\)Besides the above, patients that are considered ineligible by the principal investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials